Precise control of the standard dosage of maribavi/yitazhi

Maribavir(Maribavir) is an antiviral drug used to treatcytomegalovirus (CMV) infection. It plays a key role in antiviral treatment by inhibiting the DNA synthesis and replication ofCMV. Maribavir is approved for the treatment of CMV infection in immunosuppressed patients, particularly those who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (such as kidney, liver, or heart transplantation). The dosage and usage of maribavir should be accurately adjusted according to the patient's clinical condition and concomitant medications to ensure maximum efficacy while minimizing adverse reactions.

In the treatment of adult patients, the standard recommended dose of maribavir is 400 mg twice daily. The drug can be taken with food or on an empty stomach, giving patients greater flexibility in dosing. Standard dosages are designed to provide effective antiviral effects while minimizing the risk of side effects. During treatment, the patient's hematological and virological responses should be monitored regularly to ensure the effectiveness and safety of the medication.

In addition, dose adjustments are required when maribavivir is used with other medications. Certain anticonvulsant drugs such as carbamazepine, phenytoin, and phenobarbital can affect the blood concentration of maribavivir. These drugs accelerate the metabolism of maribavivir by enhancing liver enzyme activity, resulting in a decrease in its blood concentration, which may affect the antiviral effect. To ensure efficacy, patients taking maribavir should increase the dose of maribavir if these drugs are co-administered. Specifically, it is recommended that the dose of maribavivir be increased to 800 mg twice daily if coadministered with carbamazepine and to 1200 mg twice daily if coadministered with phenytoin or phenobarbital.

Reference materials:https://www.livtencity.com/